[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2019007684A - Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. - Google Patents

Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.

Info

Publication number
MX2019007684A
MX2019007684A MX2019007684A MX2019007684A MX2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A MX 2019007684 A MX2019007684 A MX 2019007684A
Authority
MX
Mexico
Prior art keywords
group
atom
pharmaceutically
acceptable salt
hydrogen atom
Prior art date
Application number
MX2019007684A
Other languages
English (en)
Inventor
Tamura Keiji
Yamakawa Takeru
Isshiki Satoshi
Wakiyama Yoshinari
Ouchi Shohei
Matsuhira Takashi
Ishida Natsuki
Tabata Yuji
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of MX2019007684A publication Critical patent/MX2019007684A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto representado por la Fórmula general (1) a continuación o una sal de este aceptable desde el punto de vista farmacológico: (Ver Fórmula) en la Fórmula (1), R1 y R2 pueden ser iguales o diferentes, y cada uno representa un átomo de hidrógeno, un átomo de alógeno, un grupo hidroxilo, un grupo carboxi, un grupo ciano, un grupo C1-6 alquilo opcionalmente sustituido et al.; R3 representa un átomo de hidrogeno; R4 representa un grupo heterocíclico monocíclico opcionalmente sustituido de 4 a 10 miembros que contiene 1 a 4 heteroátomos seleccionados de un átomo de oxígeno, un átomo de nitrógeno y un átomo de azufre; X representa a un grupo representado por la fórmula siguiente: -CH2-, -CH2-CH2-, -CH2-CH2-CH2- o -CH2-O-CH2-; y Z representa un átomo de hidrogeno o un grupo hidroxilo.
MX2019007684A 2016-12-26 2017-12-26 Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico. MX2019007684A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016251577 2016-12-26
JP2017089251 2017-04-28
PCT/JP2017/046610 WO2018124060A1 (ja) 2016-12-26 2017-12-26 新規化合物及びその薬理的に許容される塩

Publications (1)

Publication Number Publication Date
MX2019007684A true MX2019007684A (es) 2019-09-09

Family

ID=62709343

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007684A MX2019007684A (es) 2016-12-26 2017-12-26 Compuesto novedoso y sal de este aceptable desde el punto de vista farmacologico.

Country Status (22)

Country Link
US (1) US10669283B2 (es)
EP (1) EP3560925B1 (es)
JP (1) JP6815417B2 (es)
KR (1) KR102414365B1 (es)
CN (1) CN110114358B (es)
AU (1) AU2017385199B2 (es)
BR (1) BR112019010571A2 (es)
CA (1) CA3048170A1 (es)
CY (1) CY1124643T1 (es)
DK (1) DK3560925T3 (es)
ES (1) ES2875548T3 (es)
HU (1) HUE055468T2 (es)
IL (1) IL267594B (es)
MX (1) MX2019007684A (es)
PH (1) PH12019501391A1 (es)
PL (1) PL3560925T3 (es)
PT (1) PT3560925T (es)
RU (1) RU2767878C2 (es)
TW (1) TWI752141B (es)
UA (1) UA124353C2 (es)
WO (1) WO2018124060A1 (es)
ZA (1) ZA201904241B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021155336A (ja) * 2018-06-27 2021-10-07 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 新規ｐｄｅ４阻害剤
AR114977A1 (es) 2018-06-27 2020-11-11 Meiji Seika Pharma Co Ltd Cristales de derivado de benzoxazol
US20210315892A1 (en) * 2018-06-27 2021-10-14 Meiji Seika Pharma Co., Ltd. Therapeutic agent for inflammatory diseases, autoimmune diseases, fibrotic diseases, and cancer diseases
CN113748113A (zh) 2019-04-30 2021-12-03 艾库里斯有限及两合公司 具有抗乙型肝炎病毒(hbv)活性的新型吲哚嗪-2-甲酰胺类化合物
CN111057075B (zh) * 2019-12-24 2021-04-27 武汉九州钰民医药科技有限公司 Ret抑制剂及其制备方法
JP7476431B2 (ja) 2021-06-30 2024-04-30 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 二環性ピペラジン環を有するベンゾオキサゾール誘導体又はその塩の製造方法、並びに、その原料の製造方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61166827A (ja) 1985-01-17 1986-07-28 Toray Ind Inc 変性エポキシ系微粒子
JP3193560B2 (ja) 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
JP3520177B2 (ja) 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
PL210065B1 (pl) * 2002-09-25 2011-11-30 Memory Pharm Corp Związki indazole, benzotiazole i benzoizotiazole, kompozycje farmaceutyczne je zawierające oraz zastosowanie związków
CA2597962A1 (en) * 2005-02-17 2006-08-24 Amr Technology, Inc. Benzoxazole carboxamides for treating cinv and ibs-d
EP2061460A2 (en) 2006-08-07 2009-05-27 Albany Molecular Research, Inc. 2-aminobenzoxazole carboxamides as 5ht3 modulators
WO2009050236A1 (de) * 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Neue piperazino-dihydrothienopyrimidin-derivate
ES2714705T3 (es) * 2013-07-10 2019-05-29 Meiji Seika Pharma Co Ltd Inhibidor de PDE4 novedoso

Also Published As

Publication number Publication date
BR112019010571A2 (pt) 2019-09-17
WO2018124060A1 (ja) 2018-07-05
EP3560925B1 (en) 2021-06-02
UA124353C2 (uk) 2021-09-01
US10669283B2 (en) 2020-06-02
KR102414365B1 (ko) 2022-07-01
CY1124643T1 (el) 2022-11-25
RU2767878C2 (ru) 2022-03-22
HUE055468T2 (hu) 2021-11-29
EP3560925A1 (en) 2019-10-30
JPWO2018124060A1 (ja) 2019-10-31
CA3048170A1 (en) 2018-07-05
KR20190097235A (ko) 2019-08-20
TW201835080A (zh) 2018-10-01
EP3560925A4 (en) 2020-06-10
DK3560925T3 (da) 2021-06-28
IL267594B (en) 2022-04-01
NZ754689A (en) 2024-04-26
ZA201904241B (en) 2020-12-23
ES2875548T3 (es) 2021-11-10
AU2017385199B2 (en) 2021-09-09
PH12019501391A1 (en) 2020-02-10
RU2019122999A (ru) 2021-01-26
PT3560925T (pt) 2021-07-28
CN110114358B (zh) 2021-12-03
RU2019122999A3 (es) 2021-03-31
TWI752141B (zh) 2022-01-11
JP6815417B2 (ja) 2021-01-20
CN110114358A (zh) 2019-08-09
US20190322686A1 (en) 2019-10-24
PL3560925T3 (pl) 2021-12-20
AU2017385199A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
PH12019501391A1 (en) Novel compound and pharmacologically acceptable salt thereof
TN2018000262A1 (en) Substituted piperidine compound and use there of.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
MX2017005769A (es) Derivados policiclicos activos como plaguicidas con sustituyentes que contienen azufre.
MY192059A (en) Heterocyclic amides as kinase inhibitors
MX2017000305A (es) Derivados heterociclicos activos con sustituyentes que contienen azufre como plaguicidas.
UA116794C2 (uk) Моноциклічна піридинова похідна
MX2018000394A (es) Eteres ariloxipirimidinilicos como herbicidas.
BR112015016580A2 (pt) composto heterocíclico contendo nitrogênio ou sal deste
MY182124A (en) Pesticidally active heterocyclic derivatives with sulphur containing substituents
MX351513B (es) Compuesto de alquinilbenceno 3,5-disustituido y sales del mismo.
WO2014144545A3 (en) Substituted benzoxazoles and methods of use thereof
PH12015500209A1 (en) Partially saturated nitrogen-containing heterocyclic compound
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
MX2010013939A (es) Derivados de n-oxido pirazina sustituidos.
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
CY1121626T1 (el) Νεο παραγωγο υδροξαμικου οξεος ή αλας αυτου
MY178881A (en) Novel aqueous composition
PH12017500530A1 (en) Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
MX2013007938A (es) Compuesto biciclico novedoso o sal del mismo.
MX2022003145A (es) Compuestos de amina ciclica activos como plaguicidas.
ZA201805790B (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and &#34;azd9291 aniline&#34; or a salt thereof
MX2017001064A (es) Piridonas como herbicidas.
SG11201810725WA (en) Novel β-lactamase inhibitors
BR112013024957A2 (pt) derviado de furanona ou um sal farmaceuticamente aceitável do mesmo